Description

Paroxetine Hydrochloride USP

Paroxetine Hydrochloride USP is a high-purity, selective serotonin reuptake inhibitor (SSRI) used in pharmaceutical formulations for the treatment of major depressive disorder (MDD), anxiety disorders, and other mood-related conditions. As the hydrochloride salt of paroxetine, it provides consistent bioavailability and stability for oral solid dosage forms.

• USP-compliant SSRI for regulated psychiatric and neurologic use
• Used in oral tablets and extended-release formulations for depression, anxiety, and OCD
• Potent serotonin reuptake inhibitor with minimal norepinephrine or dopamine activity
• Suitable for monotherapy or as part of combination mental health protocols
• Manufactured under Good Manufacturing Practice (GMP) certified conditions
• Supplied with full regulatory documentation including Certificate of Analysis (CoA), Drug Master File (DMF), and supporting technical data

Paroxetine Hydrochloride is chemically designated as (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride hemihydrate. It appears as a white to off-white crystalline powder, freely soluble in water and ethanol, and is typically formulated in film-coated tablets or controlled-release formats.

In pharmaceutical applications, Paroxetine Hydrochloride USP is used in:

• Treatment of major depressive disorder (MDD) and persistent depressive states
• Generalized anxiety disorder (GAD), social anxiety, and panic disorder
• Obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD)
• Premenstrual dysphoric disorder (PMDD) and menopausal hot flashes (off-label)
• Psychiatric treatment programs requiring consistent serotonergic modulation

Paroxetine is known for its high selectivity and affinity for the serotonin transporter (SERT), making it effective in both acute and maintenance therapy. It may cause discontinuation symptoms if abruptly withdrawn and should be tapered under medical supervision.

CarboMer supplies Paroxetine Hydrochloride USP with validated control over enantiomeric purity, related substances, particle size, residual solvents, and heavy metals. Material complies with United States Pharmacopeia (USP) monograph requirements and is intended for use in regulated human pharmaceutical products.

Material is packaged in sealed, light-protective, tamper-evident containers. Available in pilot, clinical, and commercial volumes. Minimum order quantities (MOQ), lead times, and documentation—including CoA, SDS, and DMF access—are available upon request.

Each batch is tested for identity (IR, HPLC), assay (anhydrous basis), loss on drying, specific rotation, related substances, heavy metals, and microbial content. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and traceability documentation accompany every shipment.

As with all CarboMer central nervous system (CNS) APIs, Paroxetine Hydrochloride USP is supported by formulation guidance, regulatory expertise, and secure global logistics to help bring reliable mental health therapies to market.